Ingenia Therapeutics turned upward, recovering from the previous session's decline. A disclosure that the company is set to receive a milestone payment of $5 million (approximately 6.8 billion won) following the start of a global Phase 3 clinical trial of MK-8748, a candidate treatment for diabetic macular edema (DME), is drawing investor attention.

As of the morning of the 29th, Ingenia Therapeutics was trading at 24,700 won, up 350 won or 1.44% from the previous day. The stock rebounded after falling in the prior session, and its recent price trend has been relatively solid. Although it underwent some correction after the 15th, it maintained an overall upward curve through the 28th, and it returned to gains during today's session, continuing the trend. However, intraday prices may fluctuate, so further confirmation of supply-demand and volume changes is needed.

■ Global Phase 3 Trial of MK-8748 Begins... $5 Million Payment Expected

The market's key catalyst today is the milestone payment related to MK-8748. According to the disclosure, Ingenia Therapeutics licensed out MK-8748 to Eyebiotech Limited, a subsidiary of Merck & Co., Inc., on October 31, 2022, and has now achieved a milestone. The milestone was achieved through the initiation of a global Phase 3 clinical trial targeting diabetic macular edema (DME).

The payment amount is $5 million, or approximately 6.8 billion won in Korean currency. The invoice issuance date is September 25, 2026. The market sees this as confirmation that the company has entered a stage where clinical progress translates into actual licensing revenue. However, the extent to which the milestone payment is reflected in short-term share price movements may vary depending on supply-demand conditions and the broader market.

Ingenia Therapeutics is a biotech company developing treatments for ocular retinal diseases. According to the Korea Exchange's KIND, the company was newly listed on August 18, 2026.

Key checkpoints for the stock going forward are whether today's rebound extends the recent uptrend, and whether the Phase 3 entry for MK-8748 and expectations of the licensing payment act as additional supply-demand factors.

[This article is an informational piece based on disclosed corporate materials, securities firm analyses, and market data. It does not guarantee the rise or fall of any specific stock or recommend buying or selling. Securities firms' target prices and earnings forecasts may change depending on market conditions, and responsibility for investment losses lies with the investor. AI was used for some sentences and data compilation.]